Oncology’s biggest yearly event wrapped up in Chicago earlier this week, where our editor-in-chief John Carroll brought you coverage on the biggest boons and blunders for ASCO presenters.
There was the widely-covered Nektar implosion, in which the company fumbled the presentation of data on NKTR-214 — spooking investors and tanking the company’s stock as low as 42% in the days after. Then Roche dumped its PhIII PI3K effort on taselisib, and its Tecentriq/chemo combo came up short in comparison to rivals.
We created this chart based on data compiled by EP Vantage to show you just how influential ASCO data can be. In Roche’s case, it destroyed $17.4 billion in market cap value. Merck’s ASCO news, however, created $4.4 billion. Check out more below:
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription